Kenneth Mulvany is the Founder and Director of BenevolentAI. His 20 years of experience as a serial entrepreneur, investor and healthcare technology veteran give him expansive knowledge of the pharmaceutical and biotech industries; AI technology and its benefits to society; and what it takes to start-up and run a successful technology company.
Dear Benevolent Team, we have come a long way from our earliest ideas about how AI would transform pharmaceutical development in 2013 to our recent announcement of our $115m funding round - one of the largest equity investments in the rapidly emerging AI pharmaceutical sector. I am immensely proud of what we have achieved and of the inspiring talented team of people that have made it happen.
In an age where you could soon be legally (and safely) asleep at the wheel thanks to driverless cars will morality in AI go the same way – is the principle of ethics in AI asleep at the wheel?
We are developing and applying AI technology to enhance and accelerate scientific discovery by turning the world’s mass of highly fragmented scientific information into new insight and useable knowledge that ultimately benefits society.